Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Nov 30, 2010 3:23pm
726 Views
Post# 17778559

Yes I am going by the press release

Yes I am going by the press releaseanything 2 .................................which states
'' Open well logs indicate that this reservoir ( Upper Mirador ) is the most prospective in the well, which will be confirmed  by completion and testing over the next several weeks ''

Keep in mind that these '' open well logs '' are measurements of pressures at different well depths in the Mirador. And by telling us that the remaining 45  untested feet or so of the Mirador '' is the most prospective in the well ''  they are simply saying that they allready know that the high pressures required for high flow rates .......................are present.

So we are left with 2  known facts  1) There is oil in the remaining 45 feet of the Mirador
                                                               2)  High pressures have been observed which are needed for high flow rates

Now it is a function of reservoir porosity and reservoir size that will determine open flow rates. The higher the porosity and the larger the reservoir............................the greater the flow rates observed

Bullboard Posts